- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FDA panel votes against use of Roxadustat for anaemia in CKD patients
FibroGen, Inc., a leading biopharmaceutical company headquartered in San Francisco recently announced that the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) under the Food and Drug Administration (FDA) in the United States have unanimously voted to disprove the use of Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients.
The Committee backed its recommendation on a pool of information from a global Phase 3 program including more than 8,000 patients.
Chronic kidney disease (CKD) is usually a progressive disorder characterized by complete loss of kidney function that may ultimately cause kidney failure or end-stage renal disease, requiring dialysis or kidney transplant. While, anemia, which is a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, is often an early complication of CKD, affecting at least 20 percent of CKD patients.
While, Roxadustat, is an orally administered drug, the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis (red blood cell production), through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin. It is approved in China, Japan, Chile, and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) as well as not on dialysis (NDD).
Enrique Conterno, Chief Executive Officer, FibroGen, was quoted as, "While we are disappointed with today's outcome, we believe the scientific evidence supports roxadustat approval in the U.S. and will work with the FDA as it completes its review of the New Drug Application for roxadustat."
While for the FDA it is not mandatory to accept the Committee's vote, they do consider the Committee's non-binding recommendations when making their decision.
For more information refer to:
FibroGen announces outcome of FDA advisory committee review of roxadustat for treatment of anemia of chronic kidney disease. News release. FibroGen. Accessed on July 17, 2021. https://www.globenewswire.com/news-release/2021/07/15/2264019/33525/en/FibroGen-Announces-Outcome-of-FDA-Advisory-Committee-Review-of-Roxadustat-for-Treatment-of-Anemia-of-Chronic-Kidney-Disease.html.
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751